Skip to Content

Fractyl Health Inc GUTS

Morningstar Rating

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire May 13, 2024 8:00pm
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

GlobeNewswire May 13, 2024 10:00am
Fractyl Health to Present at BofA Securities 2024 Health Care Conference

GlobeNewswire May 8, 2024 10:00am
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

GlobeNewswire May 7, 2024 10:00am
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

GlobeNewswire Apr 30, 2024 12:38pm
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

GlobeNewswire Apr 2, 2024 12:00pm
Fractyl Health Shares Drop After Wider 4Q Loss

Global News Select Apr 1, 2024 11:58am
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Apr 1, 2024 11:00am
Fractyl Health Shares Rise 40% After FDA Approval of IDE for Revita

Global News Select Apr 1, 2024 10:33am
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

GlobeNewswire Apr 1, 2024 10:00am
UPDATE — Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

GlobeNewswire Mar 12, 2024 6:06pm
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

GlobeNewswire Mar 12, 2024 12:38pm
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

GlobeNewswire Feb 20, 2024 1:38pm
Wall Street hungry for IPO of Mexican supermarket chain BBB Foods as stock rises 9%

MarketWatch Feb 9, 2024 9:29pm

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.